Shiow-Lin Pan

List of Publications by Year
in descending order

63	1,272	304602	414303
papers	citations	22 h-index	32 g-index

70	70	70	2135
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Identification and analysis of a selective DYRK1A inhibitor. Biomedicine and Pharmacotherapy, 2022, 146, 112580.	2.5	8
2	Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach. Bioorganic Chemistry, 2022, 121, 105675.	2.0	10
3	O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia. Phytomedicine, 2022, 100, 154061.	2.3	5
4	Identification of a dual TAOK1 and MAP4K5 inhibitor using a structure-based virtual screening approach. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 98-108.	2.5	10
5	Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia. Journal of Natural Products, 2021, 84, 1-10.	1.5	13
6	EGFL6 promotes colorectal cancer cell growth and mobility and the antiâ€cancer property of anti-EGFL6 antibody. Cell and Bioscience, 2021, 11, 53.	2.1	6
7	A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo. Oncogenesis, 2021, 10, 39.	2.1	15
8	A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling. Biomedicine and Pharmacotherapy, 2021, 138, 111485.	2.5	4
9	Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2021, 219, 113428.	2.6	9
10	Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent. Journal of Medicinal Chemistry, 2021, 64, 17824-17845.	2.9	15
11	N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-Î³ induced PD-L1 expression. European Journal of Medicinal Chemistry, 2020, 185, 111725.	2.6	41
12	Isolation of anti-VEGF monoclonal antibodies with neutralizing effects from an Astragalus-induced immune antibody library. International Immunopharmacology, 2020, 88, 107007.	1.7	6
13	Biological Evaluation of Selected Flavonoids as Inhibitors of MNKs Targeting Acute Myeloid Leukemia. Journal of Natural Products, 2020, 83, 2967-2975.	1.5	16
14	Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells. European Journal of Medicinal Chemistry, 2020, 203, 112540.	2.6	6
15	Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury. BMC Pharmacology & Toxicology, 2020, 21, 21.	1.0	8
16	Astragalus membranaceusâ€“Derived Anti-Programmed Death-1 Monoclonal Antibodies with Immunomodulatory Therapeutic Effects against Tumors. BioMed Research International, 2020, 2020, 1-11.	0.9	8
17	A site-moiety map and virtual screening approach for discovery of novel 5-LOX inhibitors. Scientific Reports, 2020, 10, 10510.	1.6	7
18	Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimerâ€™s disease. European Journal of Medicinal Chemistry, 2020, 192, 112193.	2.6	26

#	Article	IF	Citations
19	Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2020, 190, 112086.	2.6	25
20	Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells. Bioorganic Chemistry, 2019, 91, 103119.	2.0	13
21	TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis. Theranostics, 2019, 9, 6676-6689.	4.6	24
22	Gene Expression Signature-Based Approach Identifies Antifungal Drug Ciclopirox As a Novel Inhibitor of HMGA2 in Colorectal Cancer. Biomolecules, 2019, 9, 688.	1.8	18
23	Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status. Clinical Epigenetics, 2019, 11, 85.	1.8	24
24	Potential Effects of CXCL9 and CCL20 on Cardiac Fibrosis in Patients with Myocardial Infarction and Isoproterenol-Treated Rats. Journal of Clinical Medicine, 2019, 8, 659.	1.0	27
25	MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells. Frontiers in Oncology, 2019, 9, 249.	1.3	18
26	Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 992-1003.	1.9	31
27	4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy. Bioorganic Chemistry, 2018, 77, 600-607.	2.0	6
28	1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC. European Journal of Medicinal Chemistry, 2018, 150, 667-677.	2.6	42
29	The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells. Clinical Epigenetics, 2018, 10, 162.	1.8	20
30	A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions. Frontiers in Pharmacology, 2018, 9, 1379.	1.6	26
31	A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Human Cancer Cells in Vitro and in Vivo. Frontiers in Pharmacology, 2018, 9, 205.	1.6	22
32	TMU-0324, A Novel Class I Histone Deacetylase Inhibitor, Inhibits Human Colorectal Cancer Growth <i>in vitro</i> and <i>in vivo</i>. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-6-34.	0.0	0
33	4-Indolyl- N -hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2017, 134, 13-23.	2.6	21
34	Lanatoside C, a cardiac glycoside, acts through protein kinase CÎ´ to cause apoptosis of human hepatocellular carcinoma cells. Scientific Reports, 2017, 7, 46134.	1.6	34
35	The apoptotic mechanisms of MT-6, a mitotic arrest inducer, in human ovarian cancer cells. Scientific Reports, 2017, 7, 46149.	1.6	0
36	1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma. European Journal of Medicinal Chemistry, 2017, 140, 84-91.	2.6	14

#	Article	IF	Citations
37	Overexpression of miR-194 Reverses HMGA2-driven Signatures in Colorectal Cancer. Theranostics, 2017, 7, 3889-3900.	4.6	36
38	MPT0G066, a novel anti-mitotic drug, induces JNK-independent mitotic arrest, JNK-mediated apoptosis and potentiates antineoplastic effect of cisplatin in ovarian cancer. Scientific Reports, 2016, 6, 31664.	1.6	12
39	LTP-1, a novel antimitotic agent and Stat3 inhibitor, inhibits human pancreatic carcinomas in vitro and in vivo. Scientific Reports, 2016, 6, 27794.	1.6	9
40	TW-01, a piperazinedione-derived compound, inhibits Ras-mediated cell proliferation and angioplasty-induced vascular restenosis. Toxicology and Applied Pharmacology, 2016, 305, 194-202.	1.3	1
41	Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy. Journal of Medicinal Chemistry, 2016, 59, 419-430.	2.9	68
42	Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer. Oncotarget, 2016, 7, 85917-85928.	0.8	6
43	Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo. Oncotarget, 2016, 7, 26374-26387.	0.8	18
44	Heteronemin, a Spongean Sesterterpene, Induces Cell Apoptosis and Autophagy in Human Renal Carcinoma Cells. BioMed Research International, 2015, 2015, 1-13.	0.9	29
45	N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling. Journal of Medicinal Chemistry, 2015, 58, 6549-6558.	2.9	26
46	The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. Journal of Hematology and Oncology, 2015, 8, 82.	6.9	69
47	1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells. European Journal of Medicinal Chemistry, 2015, 89, 320-330.	2.6	20
48	Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphomain vitroandin vivo. Oncotarget, 2015, 6, 4976-4991.	0.8	14
49	The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor. Oncotarget, 2015, 6, 11061-11073.	0.8	33
50	eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer. Oncotarget, 2015, 6, 24092-24104.	0.8	16
51	Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo. Oncotarget, 2015, 6, 35991-36002.	0.8	6
52	In vitro and in vivo antiâ€tumour effects of <scp>MPT0B014</scp>, a novel derivative aroylquinoline, and in combination with erlotinib in human nonâ€smallâ€cell lung cancer cells. British Journal of Pharmacology, 2014, 171, 122-133.	2.7	8
53	Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells In Vitro and In Vivo. Clinical Cancer Research, 2014, 20, 1274-1287.	3.2	44
54	Moniliformediquinone Induces In Vitro and In Vivo Antitumor Activity through Glutathione Involved DNA Damage Response and Mitochondrial Stress in Human Hormone Refractory Prostate Cancer. Journal of Urology, 2014, 191, 1429-1438.	0.2	14

#	Article	IF	Citations
55	A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I. Biochemical Pharmacology, 2014, 90, 320-330.	2.0	28
56	NPRL-Z-1, as a New Topoisomerase II Poison, Induces Cell Apoptosis and ROS Generation in Human Renal Carcinoma Cells. PLoS ONE, 2014, 9, e112220.	1.1	10
57	A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCÎ´ and E-cadherin. Oncotarget, 2014, 5, 5651-5662.	0.8	31
58	A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expression. Oncotarget, 2014, 5, 9838-9850.	0.8	11
59	Synthesis and Biological Evaluation of 1-Arylsulfonyl-5-(N-hydroxyacrylamide)indoles as Potent Histone Deacetylase Inhibitors with Antitumor Activity in Vivo. Journal of Medicinal Chemistry, 2012, 55, 3777-3791.	2.9	52
60	Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo. PLoS ONE, 2012, 7, e43645.	1.1	24
61	Baicalein attenuates intimal hyperplasia after rat carotid balloon injury through arresting cell-cycle progression and inhibiting ERK, Akt, and NF-ÎºB activity in vascular smooth-muscle cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 378, 579-588.	1.4	43
62	The indazole derivative YD-3 inhibits thrombin-induced vascular smooth muscle cell proliferation and attenuates intimal thickening after balloon injury. Thrombosis and Haemostasis, 2004, 92, 1232-1239.	1.8	23
63	The Protective Effect of Alstonia scholaris R. Br. on Hepatotoxin-induced Acute Liver Damage. The American Journal of Chinese Medicine, 1996, 24, 153-164.	1.5	40